BioMarin Pharmaceutical Inc. (BMRN) Stock

NASDAQ: BMRNDevelops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.

BioMarin Pharmaceutical stock price chart

BMRN interactive chart →

BMRN stock quote & key statistics

BioMarin Pharmaceutical earnings per share

Income →
Earnings per share

BioMarin Pharmaceutical revenue & net income

Income →
RevenueNet income

BioMarin Pharmaceutical annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$3.22B$348.9M$3.15
FY2024$2.85B$426.9M$3.14
FY2023$2.42B$167.6M$1.78
FY2022$2.10B$141.6M$1.57
FY2021$1.85B-$64.1M$0.96

Fiscal year ending December 31. Source: company filings via EODHD.

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. specializes in developing and bringing to market innovative therapies aimed at addressing severe and life-threatening rare diseases and medical conditions. The company's portfolio includes a range of advanced treatments such as Vimizim for MPS IV type A, Naglazyme for MPS VI, and Kuvan for phenylketonuria (PKU). These therapies represent cutting-edge advancements in enzyme replacement and gene therapies, catering to patients with complex metabolic and lysosomal storage disorders.

In addition to its commercial products, BioMarin is actively advancing several promising candidates through clinical trials. This includes valoctocogene roxaparvovec, currently in Phase III trials for severe hemophilia A, and BMN 307, a gene therapy in Phase 1/2 trials targeting PKU. The company's research pipeline also features BMN 255, under Phase 1/2 investigation for treating primary hyperoxaluria, showcasing its commitment to addressing unmet medical needs across diverse genetic conditions.

BioMarin serves a global market, reaching patients through specialty pharmacies, hospitals, and distribution partners across the United States, Europe, Latin America, and beyond. The company operates under strategic license and collaboration agreements with leading biopharmaceutical entities, fostering synergies that enhance its research capabilities and market reach. Since its inception in 1996 and headquartered in San Rafael, California, BioMarin continues to pioneer advancements in biotechnology aimed at transforming the lives of patients with rare diseases worldwide.

With a steadfast focus on precision medicine and genetic therapies, BioMarin Pharmaceutical Inc. remains at the forefront of innovation in biopharmaceuticals. Its dedication to improving patient outcomes through groundbreaking treatments underscores its pivotal role in advancing the field of rare disease therapeutics, offering hope and tangible solutions to individuals and families facing challenging medical conditions.

BioMarin Pharmaceutical stock FAQ

What is the BioMarin Pharmaceutical stock ticker symbol?

BioMarin Pharmaceutical Inc. trades on the NASDAQ under the ticker symbol BMRN.

What sector and industry is BioMarin Pharmaceutical in?

BioMarin Pharmaceutical Inc. is classified in the Healthcare sector, Biotechnology industry.

How many employees does BioMarin Pharmaceutical have?

BioMarin Pharmaceutical Inc. has about 3,221 full-time employees.

What were BioMarin Pharmaceutical's revenue and earnings last fiscal year?

BioMarin Pharmaceutical reported revenue of $3.22B and net income of $348.9M in fiscal 2025, with earnings per share of $3.15. Revenue grew 12.9% from the prior year.

Is BioMarin Pharmaceutical in the S&P MidCap 400?

Yes. BioMarin Pharmaceutical Inc. (BMRN) is a component of the S&P MidCap 400, the benchmark index of U.S. mid-cap stocks.

Is BioMarin Pharmaceutical in the Russell 1000?

Yes. BioMarin Pharmaceutical Inc. (BMRN) is a component of the Russell 1000, which tracks roughly the 1,000 largest U.S. companies.

When did BioMarin Pharmaceutical go public?

BioMarin Pharmaceutical stock began trading on July 23, 1999.

S&P MidCap 400 Healthcare stocks

All S&P MidCap 400 →